The efficacy of Larri® Oral Spray in the management of Laryngopharyngeal reflux disease.

INTERVENTION: Arm 1 ‐ Drug intervention arm Larri Oral Spray ‐ Magnesium Alginate,Sodium Hyaluronate, and Camellia Sinensis LARRI PDE CODES: API: 68054 SIGMA: 10028542 SYMBION: 939315 CH2: 2549021 Dose: 2 sprays, four times a day Duration: eight weeks Mode: oral spray We will call patients after four and eight weeks to monitor adherence to the intervention through verbal confirmation. CONDITION: Laryngopharyngeal reflux ; ; Laryngopharyngeal reflux Oral and Gastrointestinal ‐ Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon PRIMARY OUTCOME: Patient self reported symptom score using the "Reflux Severity Index" (RSI) questionnaire [Day 1 will be the initial survey of the questionnaire.; And then at the end of the eighth week of treatment patients will be contacted for a repeat questionnaire.] SECONDARY OUTCOME: None[N/A] INCLUSION CRITERIA: Patients who have been clinically diagnosed as having laryngopharyngeal reflux by a laryngologist and test positive for a pepsin salivary test.